Home/Pipeline/EVOLVE104

EVOLVE104

Solid Tumors

Phase 1Active

Key Facts

Indication

Solid Tumors

Phase

Phase 1

Status

Active

Company

EvolveImmune Therapeutics

About EvolveImmune Therapeutics

EvolveImmune Therapeutics is a private, clinical-stage biotech founded in 2019 and based in Branford, Connecticut. The company is developing a pipeline of trispecific T-cell engagers designed with built-in CD2 costimulation via its EVOLVE platform, targeting improved efficacy in solid tumors. Its lead program, EVOLVE104, has entered Phase 1 trials in 2025, and the company has secured a notable partnership with AbbVie. EvolveImmune is positioned in the competitive but high-potential field of next-generation T-cell engagers for oncology.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed